메뉴 건너뛰기




Volumn 22, Issue SUPPL. 1, 2009, Pages

New oral therapies may offer improved treatment options for patients with multiple sclerosis

Author keywords

Adherence; Disease modifying drugs; Multiple sclerosis; Oral therapy

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; LAQUINIMOD; PLACEBO; TERIFLUNOMIDE;

EID: 67849105036     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000347402.08903.87     Document Type: Review
Times cited : (4)

References (51)
  • 1
    • 35348845728 scopus 로고    scopus 로고
    • Emerging oral therapies for multiple sclerosis
    • Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract 2007; 61:1922-1930.
    • (2007) Int J Clin Pract , vol.61 , pp. 1922-1930
    • Cohen, B.A.1    Rieckmann, P.2
  • 2
    • 0034073705 scopus 로고    scopus 로고
    • Therapeutic developments in multiple sclerosis
    • Goodin DS. Therapeutic developments in multiple sclerosis. Expert Opin Invest Drugs 2000; 9:655-670.
    • (2000) Expert Opin Invest Drugs , vol.9 , pp. 655-670
    • Goodin, D.S.1
  • 3
    • 33744488268 scopus 로고    scopus 로고
    • Emerging therapeutic targets in multiple sclerosis
    • Fontoura P, Steinman L, Miller A. Emerging therapeutic targets in multiple sclerosis. Curr Opin Neurol 2006; 19:260-266.
    • (2006) Curr Opin Neurol , vol.19 , pp. 260-266
    • Fontoura, P.1    Steinman, L.2    Miller, A.3
  • 4
  • 6
    • 0035885062 scopus 로고    scopus 로고
    • Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice
    • Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001; 33:865-872.
    • (2001) Clin Infect Dis , vol.33 , pp. 865-872
    • Stone, V.E.1
  • 7
    • 33645227849 scopus 로고    scopus 로고
    • Patient satisfaction with an injection device for multiple sclerosis treatment
    • Cramer JA, Cuffel BJ, Divan V, et al. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 2006; 113:156-162.
    • (2006) Acta Neurol Scand , vol.113 , pp. 156-162
    • Cramer, J.A.1    Cuffel, B.J.2    Divan, V.3
  • 8
    • 0042932742 scopus 로고    scopus 로고
    • Interrupted therapy: Stopping and switching of the beta-interferons prescribed for MS
    • Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 61:551-554.
    • (2003) Neurology , vol.61 , pp. 551-554
    • Tremlett, H.L.1    Oger, J.2
  • 9
    • 35348897458 scopus 로고    scopus 로고
    • Adherence to disease-modifying therapy for multiple sclerosis
    • February
    • Cohen BA. Adherence to disease-modifying therapy for multiple sclerosis. Int J MS Care 2006; (February Suppl):32-37.
    • (2006) Int J MS Care , Issue.SUPPL. , pp. 32-37
    • Cohen, B.A.1
  • 10
    • 33746445987 scopus 로고    scopus 로고
    • Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis
    • Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2006; 38:167-171.
    • (2006) J Neurosci Nurs , vol.38 , pp. 167-171
    • Cox, D.1    Stone, J.2
  • 11
    • 0035018884 scopus 로고    scopus 로고
    • Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject
    • Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001; 23:125-132.
    • (2001) Ann Behav Med , vol.23 , pp. 125-132
    • Mohr, D.C.1    Boudewyn, A.C.2    Likosky, W.3
  • 12
    • 53249154843 scopus 로고    scopus 로고
    • Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term
    • Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 2008; 10:225.
    • (2008) Medscape J Med , vol.10 , pp. 225
    • Costello, K.1    Kennedy, P.2    Scanzillo, J.3
  • 13
    • 67849109050 scopus 로고    scopus 로고
    • Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: Findings from a national managed care database
    • Al-Sabbagh A, Bennet R, Kozma C, et al. Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database. J Neurol 2008; 255:S79.
    • (2008) J Neurol , vol.255
    • Al-Sabbagh, A.1    Bennet, R.2    Kozma, C.3
  • 14
    • 59049103985 scopus 로고    scopus 로고
    • Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis
    • Lafata JE, Cerghet M, Dobie E, et al. Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis. J Am Pharm Assoc (2003) 2008; 48:752-757.
    • (2003) J Am Pharm Assoc , vol.2008 , Issue.48 , pp. 752-757
    • Lafata, J.E.1    Cerghet, M.2    Dobie, E.3
  • 15
    • 67849109048 scopus 로고    scopus 로고
    • Comparison of adherence and persistence in patients initiating disease-modifying therapy for multiple sclerosis
    • 7-11 June, Nice, France. p
    • Meletiche D, Shea TWF, Shim B, et al. Comparison of adherence and persistence in patients initiating disease-modifying therapy for multiple sclerosis. In: Proceedings of the 18th Meeting of the European Neurological Society (ENS); 7-11 June 2008; Nice, France. p. 323.
    • (2008) Proceedings of the 18th Meeting of the European Neurological Society (ENS) , pp. 323
    • Meletiche, D.1    Shea, T.W.F.2    Shim, B.3
  • 16
    • 0142017677 scopus 로고    scopus 로고
    • Adherence to long-term therapies: Evidence for action
    • World Health Organization
    • World Health Organization. Adherence to long-term therapies: evidence for action. World Health Organization Report 2003.
    • World Health Organization Report 2003
  • 17
    • 44449148293 scopus 로고    scopus 로고
    • The impact of medication regimen factors on adherence to chronic treatment: A review of literature
    • Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008; 31:213-224.
    • (2008) J Behav Med , vol.31 , pp. 213-224
    • Ingersoll, K.S.1    Cohen, J.2
  • 18
    • 12144288676 scopus 로고    scopus 로고
    • Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on anti-retroviral-experienced patients
    • Clotet B, Carmena J, Pulido F, et al. Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on anti-retroviral-experienced patients. HIV Clin Trials 2004; 5:33-39.
    • (2004) HIV Clin Trials , vol.5 , pp. 33-39
    • Clotet, B.1    Carmena, J.2    Pulido, F.3
  • 19
    • 33745788778 scopus 로고    scopus 로고
    • Benefits, challenges, and registerability of the polypill
    • Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registerability of the polypill. Eur Heart J 2006; 27:1651-1656.
    • (2006) Eur Heart J , vol.27 , pp. 1651-1656
    • Sleight, P.1    Pouleur, H.2    Zannad, F.3
  • 20
    • 33645099736 scopus 로고    scopus 로고
    • Adherence, patient preference and dosing frequency: Understanding the relationship
    • Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006; 38:S2-S6.
    • (2006) Bone , vol.38
    • Reginster, J.Y.1    Rabenda, V.2    Neuprez, A.3
  • 21
    • 4243119542 scopus 로고    scopus 로고
    • Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease
    • Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2:12-24.
    • (2004) Health Qual Life Outcomes , vol.2 , pp. 12-24
    • Atkinson, M.J.1    Sinha, A.2    Hass, S.L.3
  • 22
    • 36148952124 scopus 로고    scopus 로고
    • Toward the development of rational therapies in multiple sclerosis: What is on the horizon?
    • Hemmer B, Hartung HP. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol 2007; 62:314-326.
    • (2007) Ann Neurol , vol.62 , pp. 314-326
    • Hemmer, B.1    Hartung, H.P.2
  • 23
    • 77955799815 scopus 로고    scopus 로고
    • Oral fingolimod (FTY720) for relapsing multiple sclerosis
    • Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355:1124-1140.
    • (2006) N Engl J Med , vol.355 , pp. 1124-1140
    • Kappos, L.1    Antel, J.2    Comi, G.3
  • 24
    • 33645799680 scopus 로고    scopus 로고
    • A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
    • O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66:894-900.
    • (2006) Neurology , vol.66 , pp. 894-900
    • O'Connor, P.W.1    Li, D.2    Freedman, M.S.3
  • 25
    • 15244353263 scopus 로고    scopus 로고
    • Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
    • Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64:987-991.
    • (2005) Neurology , vol.64 , pp. 987-991
    • Polman, C.1    Barkhof, F.2    Sandberg-Wollheim, M.3
  • 26
    • 22244480985 scopus 로고    scopus 로고
    • BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative: Fumapharm/Biogen Idec. Drugs R D 2005; 6:229-230.
    • BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative: Fumapharm/Biogen Idec. Drugs R D 2005; 6:229-230.
  • 27
    • 33947625032 scopus 로고    scopus 로고
    • Fumaric acid esters in the management of severe psoriasis
    • Brewer L, Rogers S. Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol 2007; 32:246-249.
    • (2007) Clin Exp Dermatol , vol.32 , pp. 246-249
    • Brewer, L.1    Rogers, S.2
  • 28
    • 54149116366 scopus 로고    scopus 로고
    • Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study
    • Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372:1463-1472.
    • (2008) Lancet , vol.372 , pp. 1463-1472
    • Kappos, L.1    Gold, R.2    Miller, D.H.3
  • 29
    • 36348983293 scopus 로고    scopus 로고
    • The potential role for cladribine in the treatment of multiple sclerosis: Clinical experience and development of an oral tablet formulation
    • Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin 2007; 23:2667-2676.
    • (2007) Curr Med Res Opin , vol.23 , pp. 2667-2676
    • Leist, T.P.1    Vermersch, P.2
  • 30
    • 27944443692 scopus 로고    scopus 로고
    • Cladribine for multiple sclerosis: Review and current status
    • Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 2005; 5:721-727.
    • (2005) Expert Rev Neurother , vol.5 , pp. 721-727
    • Sipe, J.C.1
  • 31
    • 0029983154 scopus 로고    scopus 로고
    • The treatment of chronic progressive multiple sclerosis with cladribine
    • Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996; 93:1716-1720.
    • (1996) Proc Natl Acad Sci U S A , vol.93 , pp. 1716-1720
    • Beutler, E.1    Sipe, J.C.2    Romine, J.S.3
  • 32
    • 0034646216 scopus 로고    scopus 로고
    • Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group
    • Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54:1145-1155.
    • (2000) Neurology , vol.54 , pp. 1145-1155
    • Rice, G.P.1    Filippi, M.2    Comi, G.3
  • 33
    • 0032908474 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis
    • Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Phys 1999; 111:35-44.
    • (1999) Proc Assoc Am Phys , vol.111 , pp. 35-44
    • Romine, J.S.1    Sipe, J.C.2    Koziol, J.A.3
  • 34
    • 67849100290 scopus 로고    scopus 로고
    • A combined analysis of data from four randomized, double-blind, placebo-controlled trials of parenteral cladribine and one open-label pilot study to assess the safety and tolerability profile of repeated periods of cladribine treatment in patients with progressive or relapsing multiple sclerosis
    • for the Cladribine Clinical Study Group, Presented at the 12-19 April, Chicago, Illinois
    • Cook SD, Gardner JD, Greenberg S, for the Cladribine Clinical Study Group. A combined analysis of data from four randomized, double-blind, placebo-controlled trials of parenteral cladribine and one open-label pilot study to assess the safety and tolerability profile of repeated periods of cladribine treatment in patients with progressive or relapsing multiple sclerosis. Presented at the 60th American Academy of Neurology Annual Meeting; 12-19 April 2008; Chicago, Illinois. P02.180.
    • (2008) 60th American Academy of Neurology Annual Meeting
    • Cook, S.D.1    Gardner, J.D.2    Greenberg, S.3
  • 35
    • 0027056958 scopus 로고
    • On the bioavailability of oral and subcutaneous 2-chloro-20-deoxyadenosine in humans: Alternative routes of administration
    • Liliemark J, Albertioni F, Hassan M, et al. On the bioavailability of oral and subcutaneous 2-chloro-20-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992; 10:1514-1518.
    • (1992) J Clin Oncol , vol.10 , pp. 1514-1518
    • Liliemark, J.1    Albertioni, F.2    Hassan, M.3
  • 36
    • 67849109049 scopus 로고    scopus 로고
    • Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial. Geneva
    • Accessed 23 January 2009
    • Merck Serono. Merck Serono's Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial. Geneva. Merck Serono; 2009. http://www.merckserono.com/ corp.merckserono/en/images/20090123-en-tcm112-34916.pdf. [Accessed 23 January 2009]
    • (2009) Merck Serono
  • 37
    • 47249153516 scopus 로고    scopus 로고
    • Modulating tone: The overture of S1P receptor immunotherapeutics
    • Rosen H, Gonzalez-Cabrera P, Marsolais D, et al. Modulating tone: the overture of S1P receptor immunotherapeutics. Immunol Rev 2008; 223: 221-235.
    • (2008) Immunol Rev , vol.223 , pp. 221-235
    • Rosen, H.1    Gonzalez-Cabrera, P.2    Marsolais, D.3
  • 38
    • 33748695513 scopus 로고    scopus 로고
    • Fingolimod and sphingosine-1- phosphatemodifiers of lymphocyte migration
    • Massberg S, von Andrian UH. Fingolimod and sphingosine-1- phosphatemodifiers of lymphocyte migration. N Engl J Med 2006; 355:1088-1091.
    • (2006) N Engl J Med , vol.355 , pp. 1088-1091
    • Massberg, S.1    von Andrian, U.H.2
  • 39
    • 53049085954 scopus 로고    scopus 로고
    • Central nervous system-directed effects of FTY720 (fingolimod)
    • Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 2008; 274:13-17.
    • (2008) J Neurol Sci , vol.274 , pp. 13-17
    • Miron, V.E.1    Schubart, A.2    Antel, J.P.3
  • 40
    • 33750736991 scopus 로고    scopus 로고
    • FTY720 (fingolimod) in renal transplantation
    • Budde K, Schutz M, Glander P, et al. FTY720 (fingolimod) in renal transplantation. Clin Transplant 2006; 20 (Suppl 17):17-24.
    • (2006) Clin Transplant , vol.20 , Issue.SUPPL. 17 , pp. 17-24
    • Budde, K.1    Schutz, M.2    Glander, P.3
  • 41
    • 67849085963 scopus 로고    scopus 로고
    • Reuters 5 June 2008, Accessed 15 December 2008
    • Cage S. Novartis says FTY720 trial continues despite death. Reuters 5 June 2008. http://uk.reuters.com/article/UK-SMALLCAPSRPT/idUKL0586762720080605? sp=true. [Accessed 15 December 2008]
    • Novartis says FTY720 trial continues despite death
    • Cage, S.1
  • 42
    • 54349101744 scopus 로고    scopus 로고
    • Identification and development of new therapeutics for multiple sclerosis
    • Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008; 29:558-565.
    • (2008) Trends Pharmacol Sci , vol.29 , pp. 558-565
    • Linker, R.A.1    Kieseier, B.C.2    Gold, R.3
  • 44
    • 0036240732 scopus 로고    scopus 로고
    • Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue
    • Zou LP, Abbas N, Volkmann I, et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 2002; 42:731-739.
    • (2002) Neuropharmacology , vol.42 , pp. 731-739
    • Zou, L.P.1    Abbas, N.2    Volkmann, I.3
  • 45
    • 45249107267 scopus 로고    scopus 로고
    • Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study
    • Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371:2085-2092.
    • (2008) Lancet , vol.371 , pp. 2085-2092
    • Comi, G.1    Pulizzi, A.2    Rovaris, M.3
  • 46
    • 25444448197 scopus 로고    scopus 로고
    • Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation
    • Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 2005; 52:2730-2739.
    • (2005) Arthritis Rheum , vol.52 , pp. 2730-2739
    • Zeyda, M.1    Poglitsch, M.2    Geyeregger, R.3
  • 48
    • 5044232705 scopus 로고    scopus 로고
    • Vasculitis associated with the use of leflunomide
    • Macdonald J, Zhong T, Lazarescu A, et al. Vasculitis associated with the use of leflunomide. J Rheumatol 2004; 31:2076-2078.
    • (2004) J Rheumatol , vol.31 , pp. 2076-2078
    • Macdonald, J.1    Zhong, T.2    Lazarescu, A.3
  • 49
    • 33846490253 scopus 로고    scopus 로고
    • Peripheral neuropathy associated with leflunomide: Is there a risk patient profile?
    • Martin K, Bentaberry F, Dumoulin C, et al. Peripheral neuropathy associated with leflunomide: is there a risk patient profile? Pharmacoepidemiol Drug Saf 2007; 16:74-78.
    • (2007) Pharmacoepidemiol Drug Saf , vol.16 , pp. 74-78
    • Martin, K.1    Bentaberry, F.2    Dumoulin, C.3
  • 50
    • 55349135951 scopus 로고    scopus 로고
    • Novel therapeutic strategies for multiple sclerosis: A multifaceted adversary
    • Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis: a multifaceted adversary. Nat Rev Drug Discov 2008; 7:909-925.
    • (2008) Nat Rev Drug Discov , vol.7 , pp. 909-925
    • Lopez-Diego, R.S.1    Weiner, H.L.2
  • 51
    • 57149117126 scopus 로고    scopus 로고
    • New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab
    • Hartung HP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 2009; 8:28-31.
    • (2009) Lancet Neurol , vol.8 , pp. 28-31
    • Hartung, H.P.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.